Updates
** Shares of medical equipment maker West Pharmaceuticals WST.N fall 3.7% to $210.19 in morning trade
** Company expects its HVP components business to grow mid-single digits instead of mid-to-high single digits, as it previously forecast
** Forecast cut came as one of WST's customers switched the type of component they were purchasing, which can currently only be supplied from one manufacturing facility, while the previous one could be sourced from multiple facilities
** This results in some stock-outs / delay in shipping this product to the customer - Nephron Research
** The business includes products to improve shelf life of packaged drugs, among others
** Company raised its annual adj EPS forecast to $6.15 to $6.35, up from $6 to $6.20
** WST reports Q1 adj. profit of $1.45/share, vs analysts' estimate of $1.23/share
** As of last close, WST stock down 33.4% YTD
(Reporting by Padmanabhan Ananthan and Puyaan Singh)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.